Interpreting big-data analysis of retrospective observational data

por Huizinga, Tom W J, Knevel, Rachel
Publicado 2020

Tweaking Microtubules to Treat Scleroderma

por van Laar, Jacob M, Huizinga, Tom W. J
Publicado 2005

Autoimmune Responses in the Rheumatoid Synovium

por Toes, Rene E. M, Huizinga, Tom W. J
Publicado 2009

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis

por Emery, Paul, Sebba, Anthony, Huizinga, Tom W J
Publicado 2013

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity

por Huizinga, Tom W. J., Torii, Yoshifumi, Muniz, Rafael
Publicado 2020

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage

por Gallo, G, Brock, F, Kerkmann, U, Kola, B, Huizinga, T W J
Publicado 2016

The role of autoantibodies in the pathophysiology of rheumatoid arthritis

por Derksen, V. F. A. M., Huizinga, T. W. J., van der Woude, D.
Publicado 2017

Glycobiology of rheumatic diseases

por Kissel, Theresa, Toes, René E. M., Huizinga, Thomas W. J., Wuhrer, Manfred
Publicado 2022

Genetics of rheumatoid arthritis: what have we learned?

por Bax, Marieke, van Heemst, Jurgen, Huizinga, Tom W. J., Toes, Rene E. M.
Publicado 2011

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’ – authors’ reply

por Markusse, Iris M., Lems, Willem F., Huizinga, Tom W.J., Allaart, Cornelia F.
Publicado 2015

Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives

por Magro-Checa, César, Zirkzee, Elisabeth J., Huizinga, Tom W., Steup-Beekman, Gerda M.
Publicado 2016

Dosing down with biologic therapies: a systematic review and clinicians’ perspective

por Edwards, Christopher J, Fautrel, Bruno, Schulze-Koops, Hendrik, Huizinga, Tom W J, Kruger, Klaus
Publicado 2018

Dosing down with biologic therapies: a systematic review and clinicians’ perspective

por Edwards, Christopher J, Fautrel, Bruno, Schulze-Koops, Hendrik, Huizinga, Tom W J, Kruger, Klaus
Publicado 2017

How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions

por Manaï, Meriem, van Middendorp, Henriët, Veldhuijzen, Dieuwke S., Huizinga, Tom W.J., Evers, Andrea W.M.
Publicado 2019

Evaluation of the Disease Activity Score in Twenty‐Eight Joints–Based Flare Definitions in Rheumatoid Arthritis: Data From a Three‐Year Clinical Trial

por Dougados, Maxime, Huizinga, Tom W. J., Choy, Ernest H., Bingham, Clifton O., Aassi, Maher, Bernasconi, Corrado
Publicado 2015

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

por Huizinga, T. W. J., Batalov, A., Stoilov, R., Lloyd, E., Wagner, T., Saurigny, D., Souberbielle, B., Esfandiari, E.
Publicado 2017

Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go?

por Magro-Checa, César, Steup-Beekman, Gerda M., Huizinga, Tom W., van Buchem, Mark A., Ronen, Itamar
Publicado 2018

Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis

por Li, Wanying, Sasso, Eric H., van der Helm-van Mil, Annette H. M., Huizinga, Tom W. J.
Publicado 2016

MR signal intensity: staying on the bright side in MR image interpretation

por Bloem, Johan L, Reijnierse, Monique, Huizinga, Tom W J, van der Helm-van Mil, Annette H M
Publicado 2018

Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the art...

por van Dijk, Bastiaan T., Trouw, Leendert A., van der Helm-van Mil, Annette H. M., Huizinga, Tom W. J.
Publicado 2020